Switching MS treatments after a relapse: does it reduce future attacks?

NCT ID NCT07743281

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study examines what happens when people with multiple sclerosis (MS) experience a relapse while on a standard treatment. It compares those who switch to a stronger, high-efficacy treatment with those who stay on their current therapy, looking at how many experience further relapses. By analyzing real-world data from 753 patients, the study aims to see if escalating treatment after a relapse is linked to better outcomes. The findings could help doctors and patients make more informed decisions about treatment changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If this study finds that escalating to a stronger treatment after a relapse reduces future relapses, it could help guide doctors in making more effective treatment decisions for people with multiple sclerosis.
What could go wrong
This is a retrospective study, meaning it looks back at past data rather than testing a new treatment in a controlled trial. It can only show associations, not proof, and results may be influenced by differences between the groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Novartis

    East Hanover, New Jersey, 07936, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.